Antonin Dréan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonin Dréan has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Idbaih
Sorbonne Université, AP-HP, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuro-Oncologie-Institut de Neurologie, F-75013, Paris, France
2 shared publications Alexandre Carpentier
AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurochirurgie, 75013, Paris, France
2 shared publicationsCharlotte Schmitt
Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 04 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, 75013, Paris, France
2 shared publicationsFranck Bielle
Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 04 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, 75013, Paris, France
2 shared publicationsFrançois-Xavier Lejeune
Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 04 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, 75013, Paris, France
2 shared publicationsJean-Yves Delattre
Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 04 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, 75013, Paris, France
2 shared publications
Latest Publications
- 16 March 2018
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 138 (3) , 487
Correction to: ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma
The names of authors Marc Sanson and Jean-Yves Delattre were incorrectly presented in the initial online publication. The original article has been corrected.
- 16 March 2018
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 138 (3) , 487
Correction to: ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma
The names of authors Marc Sanson and Jean-Yves Delattre were incorrectly presented in the initial online publication. The original article has been corrected.
- 8 March 2018
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 138 (3) , 479-486
ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma
ATP-binding cassette transporters (ABC transporters) regulate traffic of multiple compounds, including chemotherapeutic agents, through biological membranes. They are expressed by multiple cell types and have been implicated in the drug resistance of some cancer cells. Despite significant research in ABC transporters in the context of many diseases, little is known about their expression and clinical value in glioblastoma (GBM). We analyzed expression of 49 ABC transporters in both commercial and patient-derived GBM cell lines as well as from 51 human GBM tumor biopsies. Using The Cancer Genome Atlas (TCGA) cohort as a training dataset and our cohort as a validation dataset, we also investigated the prognostic value of these ABC transporters in newly diagnosed GBM patients, treated with the standard of care. In contrast to commercial GBM cell lines, GBM-patient derived cell lines (PDCL), grown as neurospheres in a serum-free medium, express ABC transporters similarly to parental tumors. Serum appeared to slightly increase resistance to temozolomide correlating with a tendency for an increased expression of ABCB1. Some differences were observed mainly due to expression of ABC transporters by microenvironmental cells. Together, our data suggest that the efficacy of chemotherapeutic agents may be misestimated in vitro if they are the targets of efflux pumps whose expression can be modulated by serum. Interestingly, several ABC transporters have prognostic value in the TCGA dataset. In our cohort of 51 GBM patients treated with radiation therapy with concurrent and adjuvant temozolomide, ABCA13 overexpression is associated with a decreased progression free survival in univariate (p < 0.01) and multivariate analyses including MGMT promoter methylation (p = 0.05) suggesting reduced sensitivity to temozolomide in ABCA13 overexpressing GBM. Expression of ABC transporters is: (i) detected in GBM and microenvironmental cells and (ii) better reproduced in GBM-PDCL. ABCA13 expression is an independent prognostic factor in newly diagnosed GBM patients. Further prospective studies are warranted to investigate whether ABCA13 expression can be used to further personalize treatments for GBM.
- 8 March 2018
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 138 (3) , 479-486
ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma
ATP-binding cassette transporters (ABC transporters) regulate traffic of multiple compounds, including chemotherapeutic agents, through biological membranes. They are expressed by multiple cell types and have been implicated in the drug resistance of some cancer cells. Despite significant research in ABC transporters in the context of many diseases, little is known about their expression and clinical value in glioblastoma (GBM). We analyzed expression of 49 ABC transporters in both commercial and patient-derived GBM cell lines as well as from 51 human GBM tumor biopsies. Using The Cancer Genome Atlas (TCGA) cohort as a training dataset and our cohort as a validation dataset, we also investigated the prognostic value of these ABC transporters in newly diagnosed GBM patients, treated with the standard of care. In contrast to commercial GBM cell lines, GBM-patient derived cell lines (PDCL), grown as neurospheres in a serum-free medium, express ABC transporters similarly to parental tumors. Serum appeared to slightly increase resistance to temozolomide correlating with a tendency for an increased expression of ABCB1. Some differences were observed mainly due to expression of ABC transporters by microenvironmental cells. Together, our data suggest that the efficacy of chemotherapeutic agents may be misestimated in vitro if they are the targets of efflux pumps whose expression can be modulated by serum. Interestingly, several ABC transporters have prognostic value in the TCGA dataset. In our cohort of 51 GBM patients treated with radiation therapy with concurrent and adjuvant temozolomide, ABCA13 overexpression is associated with a decreased progression free survival in univariate (p < 0.01) and multivariate analyses including MGMT promoter methylation (p = 0.05) suggesting reduced sensitivity to temozolomide in ABCA13 overexpressing GBM. Expression of ABC transporters is: (i) detected in GBM and microenvironmental cells and (ii) better reproduced in GBM-PDCL. ABCA13 expression is an independent prognostic factor in newly diagnosed GBM patients. Further prospective studies are warranted to investigate whether ABCA13 expression can be used to further personalize treatments for GBM.